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be averted. ConClusions: Price elasticity estimates are greater than previous 
studies in Greece and consistent with literature internationally, while income 
elasticity estimates are far greater. With cigarettes regarded as a luxury good, a 
great opportunity is presented for decison makers to counter smoking. Increased 
taxation, along with focused antismoking campaigns, law reinforcement (to ensure 
compliance with smoking bans) and intensive control for smuggling could inflict 
a massive blow to the tobacco epidemic in Greece.
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PRevalence of comoRbiditieS among chRonic coPd PatientS in the 
United StateS
Mannino M.1, Higuchi K.2, Tian H.2, Yu T.C.2, Suh K.3, Zhou H.4, Li Y.5
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objeCtives: COPD is the third leading cause of death with increasing mortality 
while other chronic condition mortality rates are decreasing. This may be due to 
the fact that COPD is a complex chronic condition with a complicated diagnosis 
and treatment guideline in an aging patient population with increasing comor-
bid conditions. The objective of this study was to understand the prevalence of 
comorbid conditions among COPD patients in the US. Methods: A retrospective 
database analysis was conducted using Marketscan Commercial and Medicare 
Supplement Data from year 1/1/2010 to 12/31/2011. Patients were included if they 
had continuous medical and pharmacy benefits coverage for at least 12 months 
after their first COPD diagnosis defined as primary or ancillary ICD-9 codes of 
491.xx, 492.xx, or 496.xx and were between the ages of 40 and 90 years old at the 
time of diagnosis. Univariate descriptive analyses were conducted to quantify 
comorbid disease prevalence. Results: Among the selected patients (n= 231,827), 
95.1% (n= 220,519) had medical claims (ICD-9 codes) for diagnoses beyond COPD 
within 12 months of their COPD diagnosis. The majority of patients were over 65 
years old (61.4%, n= 135,366). Over 60% (n= 130,325) of the patients had more than 
3 comorbid conditions. The most common were hypertension (64.9%, n= 143,189) 
(ICD-9 codes 401.xx-405.xx, 415, 416, 416.8, 459.1x and 459.3x), hyperlipidemia 
(46.5%,n= 102,498) (ICD-9 code 272.x), diabetes (27.8%, n= 61,225) (ICD-9 code 249.xx, 
250.xx, 253.5, 271.4, 357.2, 588.1, 790.29), coronary artery disease (27.4%, n= 60,364) 
(ICD-9 code 414.0x, 414.3, 414.4), and asthma (22.7%, n= 50,113) (ICD-9 code 493.
xx). ConClusions: Our results show the significant prevalence of comorbid con-
ditions among COPD patients. Further research on comorbid conditions impacting 
COPD patient treatment adherence, COPD pathogenic pathways and worsening 
overall prognosis are necessary. More evidence is required to estimate the role of 
comorbidities in COPD.
SyStemic diSoRdeRS/conditionS – clinical outcomes Studies
PSy1
examining the bURden of illneSS of veteRan PatientS diagnoSed 
with obeSity in the United StateS
Wang L.1, Xie L.2, Du J.2, Li L.1, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
objeCtives: To examine the burden of illness of diagnosed obesity in the U.S. veteran 
population. Methods: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEPT2012). 
Patients diagnosed with obesity were identified (International Classification of 
Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 278.xx) with 
the first diagnosis date designated as the index date. A group of patients without 
obesity but with the same age, region, gender and index year were identified and 
matched by baseline Charlson Comorbidity Index as a comparator group. The index 
date for the comparator group was randomly chosen to reduce selection bias. Patients 
in both groups were required to be at least 18 years old, and have 1 year of continu-
ous medical and pharmacy benefits before and after the index date. Study outcomes, 
including health care costs and utilizations, were compared between the disease 
and comparator groups by using 1:1 propensity score matching. Results: A total 
of 1,525,218 patients were identified for the obesity and comparison cohorts. After 
applying 1:1 matching, a total of 634,257 of patients were included in each group, and 
the baseline demographic and clinical characteristics were balanced. The obesity 
cohort had higher percentages of health care utilizations for inpatient (6.21% vs. 
2.92%, p< 0.01), emergency room (11.96% vs. 7.28%, p< 0.01), physician office (99.84% vs. 
60.12%, p< 0.01), outpatient (99.86% vs. 60.85%, p< 0.01), and pharmacy visits (89.01% 
vs. 61.71%, p< 0.01) than the comparator group. Patients diagnosed with obesity 
also incurred higher expenditures in inpatient ($1,812 vs. $875, p< 0.01), emergency 
room ($117 vs. $69, p< 0.01), physician office ($2,936 vs. $1,436, p< 0.01), outpatient 
($3,288 vs. $1,621) and pharmacy visits ($641 vs. $423, p< 0.01) compared to non-obese 
patients. ConClusions: Study results suggest that patients diagnosed with obesity 
incurred significantly higher costs and utilizations than non-obese patients.
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objeCtives: To compare clinical efficacy and safety of orphan drug deferasirox 
(DSX) versus deferoxamine (DFO) in the treatment of paediatric patients (age ≤ 18 
years) with iron overload from repeated blood transfusions. The underlying con-
ditions requiring transfusion included beta-thalassaemia, sickle cell disease and 
other congenital and acquired anaemias (myelodysplastic syndromes, Diamond-
Blackfan syndrome, aplastic anaemia and other very rare anaemias). Methods: 
We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled 
trials (RCTs) published up to April 2012. The review was conducted in accordance 
ability of prescription of asthma medications, there appears to be an unmet need 
and further research is necessary.
PRS61
economic evalUation of enhanced aSthma management: a 
SyStematic Review
Yong Y.V., Shafie A.A.
Universiti Sains Malaysia, Penang, Malaysia
objeCtives: To evaluate, compare, and assess the quality of the studies on the cost-
effectiveness of enhanced management (either as adjunct to usual care or alone) 
vs.usual care alone or none at all. Methods: Scientific databases (ScienceDirect, 
Wiley Online Library, (EbscoHost – MEDLINE, CINAHL, PSYInfo), (OvidSP – EMBASE, 
MEDLINE), and Scopus) were searched for published journal articles in English lan-
guage from year 1990 to 2012, using the search terms “asthma AND (intervene OR 
manage) AND (pharmacoeconomics OR economic evaluation OR cost effectiveness OR 
cost benefit OR cost utility)”. Hand search was done for local publishings. Only studies 
with full economic evaluation on enhanced management (either as adjunct to usual 
care or alone) were included. Selected studies were data abstracted and assessed for 
their quality of economic evaluation using the Quality of Health Economic Studies 
(QHES) instrument, and quality of evidence. Results: A total of 14 studies were 
included. There were three distinct modes reviewed: environmental control, self-
management, education. Most of the enhanced managements were found to be cost-
effective with ICER ranged from dominant to $26700.00 per unit of outcome. Overall, 
the mean score of QHES was 76.69% (SD 9.26). For the quality of evidence, ‘clinical 
effect sizes, adverse events & complication’, baseline clinical data, resourse use, and 
costs components were ranked mainly 1 or 2 (best or nearly best) in all studies. For 
‘utilities’ component, one study ranked 5 because it used visual analogue scale to 
obtain patient preference values. ConClusions: Despite the low qualities of the 
reviewed studies, it overall suggests that enhanced management (either as adjunct 
to usual care or alone) is mostly cost-effective than the usual care or none at all; 
environmental control is considered the most cost-effective, and there is also strong 
evidence for self-management, but provided the mode of it is made available, afford-
able, and accessible then this shall be worth to be adapted in one’s setting.
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objeCtives: Economic evaluation of the change in market dynamics of a sample 
ProductA1 through its inclusion in Therapeutic Equivalence Band (TEB) (with products 
B2 and C3) between 2010 and 2012 in Turkish health care system. Methods: IMS 
Dataview was analyzed for 2010-2012 unit sales values (market entry timeline for 
products A, B, C is 2006, 2009 and 2009, respectively) in the TEB. IMS Medical Index is 
used for estimating prescription data for the corresponding products. Assumptions on 
median patient adherence (receipt of prescribed treatment in pharmacy) are applied 
to prescription data in order to calculate unit sales (prediction). Deviation calcu-
lations and sensitivity analysis on market dynamics were performed in Microsoft 
Excel-2007. Results: Deviations between unit sales predictions and realizations 
for products A, B and C occurred as +11.48%, -5.41% and -20.85% in 2010, -10.16%, 
+8.14% and -53.87% in 2011 and -31.89%, +28.92% and -67.76% in 2012 respectively. 
Negative deviation values indicate that receipt of prescription cannot be transformed 
to receipt of the prescribed product in pharmacy, however positive deviation values 
correspond to receipt of a product in pharmacy which is different from the content of 
the prescription. ConClusions: The TEB system allows receipt of a different product 
than prescription. This study shows alteration of market dynamics in pharmacy as a 
change from prescribed inhaler option (as negative deviation value), which is linked 
to receipt of another inhaler option (as a positive deviation value) within the same 
TEB. Real life data may be collected for further analysis of TEB system in dynamics 
of corresponding market. 1Originator treatment in TEB-Novartis-Budesonide(400m
cg)&Formoterol(12mcg), 2Second treatment in TEB-Bilim Pharma, 3Third treatment 
in TEB-Abdi Ibrahim Pharma.
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eStimateS of PRice and income elaSticity in gReece: gReek debt cRiSiS 
tRanSfoRming cigaRetteS into a lUxURy good
Tarantilis F., Athanasakis K.
National School of Public Health, Athens, Greece
objeCtives: Greece was long reported to show a smoking prevalence over 40% on 
adult population, as efforts to constrain smoking were rather ineffective. Following 
a sharp fall in cigarette consumption for 2012, our objective is to assess smokers’ 
sensitivity to cigarette price and consumer income changes as well as to project 
health benefits of an additional tax increase. Methods: Analysis includes the 
conventional model of demand, the myopic addiction model and the rational 
addiction model. Cigarette consumption for the period 1994-2012 was the depend-
ent variable with Weighted Average Price as a proxy for cigarette price, GDP as a 
proxy for consumer income and dummy variables reflecting smoking restrictions 
and antismoking campaigns. Values were computed to natural logarithms and 
regression was performed. Then, 4 scenarios of tax increase were distinguished in 
order to calculate potential health benefits. Results: Addiction models are una-
ble to provide statistically significant information following a nearly 23.5% drop 
in consumption during 2012. Short-run price elasticity is estimated at -0.441 and 
short-run income elasticity is estimated at 1.040. Antismoking campaigns were 
found to have a statistically significant impact on consumption. Results indicate 
that, depending on the level of tax increase, annual per capita consumption could 
fall by up to 607.99 cigarettes; tax revenue could rise by at least € 39 million, while 
up to 595,866 smokers could quit and up to 2,696 smoking related deaths could 
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objeCtives: CTEPH is a progressive and commonly fatal disease. A systematic 
literature review was conducted to synthesize evidence on mortality and survival 
in patients with inoperable CTEPH or residual/recurrent pulmonary hyperten-
sion (PH) after pulmonary endarterectomy (PEA). Methods: Using specific search 
terms, we systematically searched for MEDLINE- and EMBASE-indexed studies on 
the epidemiology of CTEPH in various regions (including Western Europe, North 
America, New Zealand, or Australia) without temporal limits. Among these stud-
ies, we identified those that reported mortality and/or survival for patients with 
inoperable CTEPH or residual/recurrent PH post-PEA. These studies then under-
went analytical narrative synthesis. Results: In all, 71 articles met the criteria 
for acceptance into the review. Of these, 21 described mortality or survival in 
patients with inoperable CTEPH or residual/recurrent PH post-PEA. The propor-
tion of patients with inoperable disease was 27%–41% in seven registries and 
retrospective studies in Europe. The proportion of patients who underwent PEA 
was 59%–69% in two Canadian studies and 10%–65% (median 50%) in 11 European 
studies. Among studies with ≥ 18 months of follow-up, mortality was higher in 
patients with inoperable CTEPH (13.4%–58%, with seven of 10 studies reporting 
mortality rates of 13.3%–21.4%) than among those with residual/recurrent PH 
post-PEA (7.4% after a mean follow-up of 50 months). Overall survival was lower 
among patients with inoperable CTEPH than among those with residual/recurrent 
PH post-PEA. Survival rates for inoperable CTEPH were 73%–93% at one year (10 
studies), 41%–88% at three years (nine studies), and 53%–88% at five years (five 
studies). In contrast, patients with residual/recurrent PH post-PEA had five-year 
survival rates of 89.9%–100% (three studies). ConClusions: Inoperable CTEPH 
carries a particularly poor prognosis, with survival rates lower even than those 
for patients who have residual/recurrent PH following PEA.
PSy6
analySeS adjUSting foR Selective cRoSSoveR Show imPRoved oveRall 
SURvival with decitabine comPaRed with tReatment choice in daco-
016 PhaSe iii tRial
Tomeczkowski J.1, Güntert A.1, Thilakarathne P.2, Diels J.2, Xiu L.3, Tapprich C.1
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen Pharmaceutica, Beerse, Belgium, 3Janssen-Cilag 
Limited, Raritan, NJ, USA
objeCtives: Among patients with acute myeloid leukemia (AML), the DACO-016 
randomized study showed reduction in mortality for DACOGEN®(decitabine, DAC) 
compared with treatment choice (TC): at primary analysis the Hazard Ratio (HR) 
was 0.85 (95% CI: 0.69- 1.04; stratified log-rank p= 0.108). With two interim analyses, 
2-sided alpha was adjusted to 0.0462. With one year additional follow-up the HR 
reached 0.82 (nominal p= 0.037). These data, together with significant outcomes in 
secondary endpoints and a positive benefit-risk resulted in approval of DACOGEN 
in the EU, however not in the US. With the primary analysis only showing a strong 
trend, the French Haute Autorité de Santé negated a mortality benefit. Though pre-
specified, the log-rank test could be considered not optimal to assess the observed 
survival difference because of the non-proportional hazard nature of the survival 
curves. We applied the Wilcoxon test as a sensitivity analysis. Methods: Patients 
(age ≥ 65 years, ineligible for chemotherapy) were randomized to DAC (N= 242) or TC 
(N= 243). For testing the observed treatment effect, Wilcoxon-test is considered more 
powerful in the context of non-proportional hazard curves compared to the log-rank 
test, as the former assigns more weight to earlier events. Results: A total of 108 
(44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively 
crossed over to subsequent disease modifying therapies at progression, which might 
impact the survival beyond the median with resultant converging curves (and dis-
proportional hazards). The Wilcoxon-test stratified by baseline age, cytogenetic-risk 
and ECOG performance status showed a significant improvement in OS with DAC 
(7.7 [6.2; 9.2] months) versus TC (5.0 [4.3; 6.3] months) (p= 0.0456). ConClusions: 
Wilcoxon-test indicated significant increase in survival for DAC vs TC in patients 
with AML compared to log-rank test at primary analysis.
SyStemic diSoRdeRS/conditionS – cost Studies
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bUdget imPact analySiS of defeRaSiRox in the tReatment of non 
tRanSfUSion dePendent thalaSSemia in gReece
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objeCtives: Deferasirox is an oral iron chelator that has demonstrated efficacy in 
reducing excess liver iron concentration (LIC) in iron overloaded non-transfusion 
dependent thalassemia (NTDT) patients. This analysis estimated the budget impact 
of reimbursing deferasirox in Greece. Methods: An open cohort budget impact 
model was developed from the Greek health care system perspective over 5 years. 
Comparators included deferoxamine, deferiprone, and combination therapy (defer-
oxamine plus deferiprone). NTDT prevalence, drug acquisition and administration 
costs were from Greece (2013 € ). No discounting was applied. Deferasirox clinical 
inputs were derived from the THALASSA trial. Rate of reduction in LIC (decrease 
of 26%) was applied each year for deferasirox. This was assumed the same for all 
comparators. Patients remained on treatment until the 3 mg Fe/gr dw discontinua-
tion threshold for LIC was reached. Treatment was reinitiated when LIC increased 
above 5 mg Fe/gr dw. Base case starting age was 10 years. Sensitivity analysis was 
performed on key model inputs. Results: A total of 280 patients with NTDT were 
estimated to be treated with iron chelation per year. With no deferasirox, total drug 
acquisition and administration costs were € 3,545,406 and € 11,889,133, respec-
tively. With the introduction of deferasirox, acquisition costs increased by 62% to € 
5,738,323 and administration costs decreased by 58% to € 4,993,474. Total expendi-
ture decreased by over 30% representing cost savings of € 4,702,742 over 5 years. 
Results were sensitive to acquisition costs, administration costs for deferoxamine, 
treatment efficacy and discontinuation threshold. ConClusions: Reimbursement 
of deferasirox in NTDT resulted in cost savings to the Greek health care system. 
with the Cochrane Collaboration guidelines and the Polish Agency for Health 
Technology Assessment recommendations. Calculations were performed using 
the StatsDirect®2.6.8 statistical package. Results: : As a result of the systematic 
literature search 2 primary RCTs (subtype II A), satisfying the inclusion criteria 
were found: Cappellini 2006 (patients with beta-thalassaemia) and Vichinsky 2006 
(patients with sickle cell disease). The results of the performed analysis proved 
that once-daily oral deferasirox showed similar efficacy to parenteral deferoxamine 
therapy in terms of decreased in LIC (liver iron concentration) and SF (serum fer-
ritin). Treatment adherence was similar in both DSX and DFO groups. Safety analysis 
showed that deferasirox was safe and well-tolerated therapy. The most frequent 
adverse events in the deferasirox group were diarrhea, nausea, vomiting, abdominal 
pain and skin rash. In most cases, analysed adverse events were mild and transient. 
Discontinuation rates were similar in both DSX and DFO arms. ConClusions: 
Deferasirox represents an important once-daily oral agent for the treatment of 
chronic iron overload due to blood transfusions. Once-daily oral deferasirox has 
acceptable tolerability and similar efficacy to parental deferoxamine in reducing 
iron burden in transfused paediatric patients. Moreover, deferasirox improves 
patients’ quality of life, may improve patient’s compliance with treatment and 
reduces morbidity and mortality from iron overload.
PSy3
meta-analySiS of efficacy of RomiPloStim foR tReatment of immUne 
idioPathic thRombocytoPenia
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune con-
dition characterized by increased platelet destruction and suboptimal platelet 
production, resulting in low platelet counts (thrombocytopenia). Romiplostim has 
shown efficacy in increasing platelet counts. The objective of this study was to 
conduct meta-analysis and present total evidence for Romiplostim for treatment 
of ITP. Methods: For this meta-analysis we included randomized controlled tri-
als (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs 
that compared romiplostim versus placebo for management of ITP, had a treat-
ment duration of at least 24 weeks, were doubleblind (patients and investigators 
blinded) and reported data on platelet response. A systematic literature search 
for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, interventions, 
year, and the two outcomes overall and durable platelet response rate. For meta-
analysis, random effects and fixed effects models were used to obtain cumulative 
statistics. Results: Two RCTs with a total of 125 patients were identified. The 
pooled response rates for Romiplostim for overall platelet response rate were 
82% (95% CI 73%-90%); and for durable platelet response rate were 48% (95% CI 
26%-71%). The pooled response rates for placebo for overall platelet response rate 
were 7% (95% CI 0%-15%), and for durable platelet response rate were 2% (95% CI 
0%-4%). For overall platelet response rate the cumulative relative risk with placebo 
versus Romiplostim was 0.09 (95% CI 4%-14%). For durable platelet response rate, 
the cumulative relative risk with placebo versus Romiplostim was 0.03 (95% CI 
0%-6%). ConClusions: Meta-analysis shows Romiplostim offers patients with 
Immune idiopathic thrombocytopenia an effective therapeutic option for increas-
ing platelet counts.
PSy4
biS SenSoR veRSUS conventional aneSthetic monitoRing: SyStematic 
Review on Patient-oRiented oUtcomeS
Nobre M.R.C., Costa F.M.
InCor - HCFMUSP, São Paulo, Brazil
objeCtives: Adult patients who receive general anesthesia may not remain totally 
unconscious during surgery despite of anesthetics and analgesics care received. The 
retention of memory due to intraoperative awareness may cause serious clinical 
complications, requiring 1071 patients monitored to prevent the occurrence of one 
event. The proper conventional maintenance of general anesthesia is assessed with 
clinical signs or expired gases (ETAC/ETAG/ETCO2). Bi-Spectral Index Monitoring or 
BIS Sensor is a neurophysiological evaluation system that continually analyzes EEG 
to determine the level of intraoperative awareness. Methods: We have made a lit-
erature search in PubMed to identify systematic reviews and randomized controlled 
trials that studied level of consciousness intraoperative or postoperative memory 
when used these alternatives of anesthetic monitoring. Results: We have found 
nine RCT and two systematic reviews published until April 2013 and conducted our 
own meta-analysis on seven trials. Two studies were excluded from the synthesis for 
not presenting the outcome of primary interest. Three RCT of moderate heterogene-
ity showed no difference in the occurrence of intraoperative awareness between the 
BIS group and the ETAC/ETAG/ETCO2 group. The quality of evidence was considered 
high in one study, moderate and low in the others (26,490 patients, I2 = 45.9%, RR = 
1.28, 95% CI = 0.54 to 3.03, p = 0.57). Four clinical monitoring control group studies 
with no heterogeneity showed that the sensor BIS was more effective, requiring 
between 71 and 167 patients monitored for an event of intraoperative awareness 
avoided. The quality of evidence of the studies was considered high (7,779 patients, 
I2 = 0.0%, RR = 0.42, 95% CI = 0.27 to 0.65, p = 0, 0.0001). ConClusions: Clinical 
trials published until April 2013 showed favorable results in patient-oriented out-
comes of BIS group when compared to clinical monitoring group but not to ETAC/
ETAG/ETCO2 group.
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chRonic thRomboembolic PUlmonaRy hyPeRtenSion (ctePh): a 
SyStematic liteRatURe Review
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